



Atty. Dkt. No. 074129-0488

4
203
12-13-01

TECH CENTER 1600/2900

OCT 23 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Katsumi IGA et al.
Title: PERCUTANEOUS ABSORPTION PREPARATION OF COMPOUND
HAVING ANGIOTENSIN II ANTAGONISTIC ACTIVITY
Appl. No.: 09/913,516
Filing Date: August 15, 2001
Examiner: Unassigned
Art Unit: 1614

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

Document B1 relates to the use of antioxidants for the treatment of inflammatory skin diseases.

Document B2 relates to the use of a 3-alkoxy-pyridine derivative with non-peptide angiotensin II acceptor antagonism activity – to prevent or treat intravascular membrane hypertrophy due to e.g. reconstriction after PTCA and arteriosclerosis.

Document B3 relates to an Aq. suspension liquid for treating cataract and corneal disorders – comprises 5- (3ethoxy-4-N-pentyl-oxyphenyl)-thiazolidine-2, 4- dione fine crystals, aq. Macromolecular cpd., chloro-butanol and benzalkonium chloride.

Document B4 was cited in the International Preliminary Examination Report in Applicants' International Application No. PCT/JP00/00926. A copy of document B4 is not being provided since a copy should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO. A copy of the International Preliminary Examination Report setting forth the portion of each reference considered relevant by the examiner is attached.

English translations of the foreign-language documents are not readily available. However, the absence of such translations does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609). English language abstracts are provided for documents B1 through B3.


Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date October 19, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5571
Facsimile: (202) 672-5399

By 
for Harold C. Wegner *Reg No 35,264*
Attorney for Applicant
Registration No. 25,258